People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according ...
May 5, 2026
0
8
Biomedical engineers at Duke University have developed a new approach to delivering GLP-1 medications orally that does not require fasting and maintains their efficacy. The technique could also be useful for any pharmaceutical ...
May 19, 2026
0
8
Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and ...
May 6, 2026
0
8
Thanks to advances in AI, popular calorie-tracking apps can now use a photo of a meal to estimate the nutritional content of what you're eating. Although these apps are convenient, a new study found that four photo-based ...
Jul 25, 2026
0
8
A new clinic-ready web-based risk prediction tool called PsyMetRiC is now available to forecast the risk of young people with psychosis developing cardiometabolic disorders such as obesity, metabolic syndrome and diabetes.
Mar 11, 2026
0
8
Peptide may not yet be the 2026 Oxford Word of the Year, but it must surely be in the running. From your friendly neighborhood influencer to the gym bros, injectable peptides have been all over social media and are now making ...
Jul 7, 2026
0
8
Hip dips are having a moment. The perfectly normal indentations that sit below your hips on the outer thigh have become the latest body feature to be scrutinized, fixed and agonized over on social media. But what are they? ...
Jun 10, 2026
0
8
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious ...
Jun 6, 2026
0
8
A new daily pill to help with weight loss has been approved by the U.S. Food and Drug Administration (FDA), and it moved through review faster than most drugs in recent years.
Apr 2, 2026
0
8
Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter ...
Jun 12, 2026
0
8
